Roivant Sciences ROIV
NASDAQ ROIV
$35.72 +0.22 (+0.62%)
At close: Oct 2, 2026 · 4:00 PM EDT

Roivant Sciences (ROIV) Liabilities from Discontinued Operations (2024)

Updated

Roivant Sciences (ROIV) recorded Liabilities from Discontinued Operations of $433.95 million in fiscal Q4 2024 (quarter ended Mar 31, 2024).

Analysis

Roivant Sciences (ROIV) Liabilities from Discontinued Operations (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn
10 Roivant Sciences 25.65 Bn 26.35 Bn 1.16 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 433.95 Mn
API Access

Roivant Sciences Liabilities from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-from-discontinued-operations&ticker=ROIV&period=max&api_key=YOUR_API_KEY